HELLP综合征凝血功能与血管性血友病因子抗原水平的变化及意义
结果显示HELLP组Fib、D-二聚体、vWF:Ag均显著高于对照组,AT显著降低,PT和APTT两组均在正常参考范围。按血小板减少程度分层,轻度26例、中度22例、重度17例,随病情加重D-二聚体、Fib、vWF:Ag显著升高而AT显著降低。结论提示HELLP综合征患者可能存在高凝状态及vWF:Ag过度表达,可诱导血小板聚集导致血小板减少和血栓性微血管病。
要点
- HELLP综合征患者vWF:Ag显著高于正常晚孕妇女[516.50(467.20, 563.00)% vs. 246.45(189.95, 274.10)%,P<0.01]。
- HELLP综合征患者AT显著低于正常晚孕妇女[62.00(49.00, 73.00)% vs. 97.50(90.75, 107.00)%,P<0.01]。
- HELLP综合征患者Fib和D-二聚体显著高于对照组[Fib(g/L):4.94(4.76, 5.85)vs. 3.58(2.97, 4.14);D-二聚体(mg/L):3.34(2.55, 4.32)vs. 1.72(1.29, 2.08),均P<0.05]。
- 随血小板减少程度加重(轻度PLT>100×10^9/L、中度(50-100)×10^9/L、重度PLT<50×10^9/L),D-二聚体、Fib、vWF:Ag显著升高而AT显著降低(均P<0.05)。
- HELLP综合征患者PT和APTT均在正常参考范围,不能仅凭PT/APTT正常排除凝血异常。
适用人群与场景
- 均为育龄期女性,两组基线资料无显著差异。
诊断标准与关键阈值
- HELLP综合征按血小板减少程度分层:轻度PLT>100×10^9/L(26例),中度PLT(50-100)×10^9/L(22例),重度PLT<50×10^9/L(17例)。
- 凝血指标参考:PT和APTT两组均在正常参考范围。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- HELLP综合征患者出现血小板减少加重时,D-二聚体、Fib、vWF:Ag显著升高而AT显著降低,提示高凝状态及血栓性微血管病可能,临床应关注。
研究设计与关键结果
- 研究类型:回顾性分析;样本量:HELLP综合征65例、正常晚孕妇女65例;单中心(天津市第五中心医院重症医学科)。
- 主要终点:HELLP组vs对照组Fib(g/L)4.94(4.76, 5.85)vs. 3.58(2.97, 4.14),D-二聚体(mg/L)3.34(2.55, 4.32)vs. 1.72(1.29, 2.08),均P<0.05;AT 62.00(49.00, 73.00)% vs. 97.50(90.75, 107.00)%,P<0.01;vWF:Ag 516.50(467.20, 563.00)% vs. 246.45(189.
- 按血小板减少程度分层(轻度、中度、重度):D-二聚体(mg/L)2.63(2.60, 2.73)、3.15(2.55, 3.73)、3.84(3.52, 4.23);Fib(g/L)4.23(4.06, 4.47)、4.72(4.34, 5.04)、5.43(5.14, 5.76);vWF:Ag 465.20(437.20, 495.40)%、500.10(472.40, 534.50)%、543.50(521.30, 563.00)%
证据类型、等级与局限
- 证据类型:回顾性分析;原文未述证据等级或推荐强度。
- 局限:原文未述局限性。
对床旁实践的改变
- 对HELLP综合征患者,除监测血小板外,应关注Fib、D-二聚体、AT及vWF:Ag水平变化,以评估高凝状态及血栓性微血管病风险。
- PT和APTT正常不能排除HELLP综合征的凝血异常,需结合Fib、D-二聚体、AT、vWF:Ag综合判断。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the changes and clinical significance of blood coagulation function and von Willebrand factor antigen (vWF:Ag) in patients with HELLP syndrome (hemolysis, elevated liver function, low platelet count).
METHODS: The clotting data of patients with severe preeclampsia and HELLP syndrome (observation group) admitted to the department of critical care medicine of the Fifth Center Hospital in Tianjin from May 2015 to December 2019 were retrospectively analyzed, and normal late pregnancy women with the same period were enrolled as the control group. The coagulation indexes such as prothrombin time (PT), activated partial thrombin time (APTT), antithrombin (AT), fibrinogen (Fib), D-dimer and plasma vWF:Ag level were compared between the two groups, and among patients with HELLP syndrome with different disease degree.
RESULTS: (1) Sixty-five patients with HELLP syndrome and 65 normal pregnant women with third trimester were included. Both groups were women of childbearing age, and there were no significant difference in the baseline data. (2) The levels of Fib, D-dimer in both groups increased, but they were significantly higher in the observation group than those in the control group [Fib (g/L): 4.94 (4.76, 5.85) vs. 3.58 (2.97, 4.14), D-dimer (mg/L): 3.34 (2.55, 4.32) vs. 1.72 (1.29, 2.08), both P < 0.05], the AT was obviously reduced [62.00 (49.00, 73.00)% vs. 97.50 (90.75, 107.00)%, P < 0.01], and both PT and APTT were in the normal reference range in the two groups. In addition, the plasma vWF:Ag level in the observation group was significantly higher than that in the control group [516.50 (467.20, 563.00)% vs. 246.45 (189.95, 274.10)%, P < 0.01]. (3) According to thrombocytopenia, among the 65 patients with HELLP syndrome, 26 cases were mild [platelet count (PLT) > 100×109/L], 22 cases were moderate [PLT (50-100)×109/L], and 17 cases were severe (PLT < 50×109/L). With the aggravation of the disease, the D-dimer, Fib, vWF:Ag levels in the mild, moderate, severe patients significantly increased, while the AT level significantly decreased, and there was statistically significant difference between the two groups [D-dimer (mg/L): 2.63 (2.60, 2.73), 3.15 (2.55, 3.73), 3.84 (3.52, 4.23); Fib (g/L): 4.23 (4.06, 4.47), 4.72 (4.34, 5.04), 5.43 (5.14, 5.76); vWF:Ag: 465.20 (437.20, 495.40)%, 500.10 (472.40, 534.50)%, 543.50 (521.30, 563.00)%; AT: 67.50 (61.60, 78.00)%, 63.70 (53.30, 70.40)%, 54.40 (44.00, 61.20)%; all P < 0.05].
CONCLUSIONS: Patients with HELLP syndrome may show hypercoagulability and excessive expression of peripheral blood vWF:Ag level, which can induce platelet aggregation, leading to thrombocytopenia and thrombotic microangiopathy, and the clinicians should pay attention to that.
参考来源
- Chu X, Wang W, Zhang H, et al. [Change and significance of coagulation function and von Willebrand factor antigen level in HELLP syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33081902. doi:10.3760/cma.j.cn121430-20200601-00447
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。